Bristol Myers Squibb said Friday that its experimental oral drug mezigdomide improved cancer-free survival by more than 50% in a Phase 3 trial [1].
The results are significant for patients with relapsed or refractory multiple myeloma, a form of blood cancer that is often difficult to treat. The success of the drug could provide a new therapeutic option for those who have failed previous treatments.
Mezigdomide was administered as part of a combination regimen during the late-stage clinical study [2]. The company said the drug delayed disease progression and boosted progression-free survival by more than 50% compared with the control group [1].
Multiple myeloma patients in the global study showed improved outcomes when using the oral medication [2]. The trial focused specifically on patients whose cancer had either returned after a period of remission, or had not responded to standard therapies [3].
Bristol Myers Squibb is positioning mezigdomide to eventually succeed its Revlimid franchise [3]. Revlimid has been a cornerstone of the company's multiple myeloma market presence, and the new drug aims to offer a more effective alternative for high-risk patients [4].
The company said these findings on May 29, 2024 [5]. While the specific sites of the global study were not disclosed, the Phase 3 trial is the final step before a pharmaceutical company typically seeks regulatory approval for a new medication [2].
“Cancer-free survival improved by more than 50% compared with control”
The success of mezigdomide represents a strategic pivot for Bristol Myers Squibb as it seeks to replace the aging Revlimid franchise with a next-generation therapy. By targeting relapsed or refractory patients—the most difficult population to treat—the company is attempting to secure a dominant position in the oncology market while addressing a critical unmet medical need in blood cancer care.
